A significant development in the field of human biology is the revelation of millions of unannotated protein sequence variants emerging from the several human genotyping and genome sequencing initiatives. This presents unique opportunities as well as confounding challenges in our understanding of how molecular signalling outcomes vary among individuals in the general population. As a result the conventional 'one drug fits all' lines of approach in the drug discovery process is becoming obsolete. However, an innovative genotype-specific approach targeting protein sequence variants instead of a reference protein target is currently lacking. In this short communication we report a remarkable observation of antibody-mediated knockdown of intracellular protein expression. This suggests allelespecific inhibition of protein-variant expression can be achieved by intracellular delivery of lipid conjugated linear epitope-specific monoclonal antibodies. The results presented here demonstrate novel opportunities for interrogating the protein coding variations in the human genomes and new therapeutic strategies for the inhibition of pathogenic protein variants in a genotype-centric manner.
Introduction
With over five decades after the discovery of DNA double helix and over a decade after the complete sequencing of human genome we are still faced with the challenge of effectively dealing with aberrant and mutated proteins as underlying cause of many diseases.
Furthermore new challenges arise with the ever-increasing knowledge of genomic variations prevalent among human populations. This calls on for a serious rethinking on the existing conventional strategy of drug discovery process based on "one drug fits all". Recently, the prospect of identifying the genetic basis of diseases in the current genomic era has enormously increased. However, the big question of how to tackle specifically these disease causing protein variants without affecting the normal healthy alleles has remained unanswered. Small molecule chemical inhibitors purported to inhibit such mutated protein targets, often are binding and inhibiting multiple other proteins as well as wild type protein causing undesirable side effects. There are some positive anticipation from RNA interference and more recently the genome editing CRISPR technologies for knocking down specific proteins (Howard, 2003; Marraffini & Sontheimer, 2010) . But these techniques have their limitation in not being able to distinguish protein variants differing in single amino acid change. While the recent genomic revolution has uncovered many patient specific targets in complex diseases such as cancer, the pace of discovering personalized solutions is still lagging behind (Drews, 2000; Roses, 2004 ).
Here we report a phenomenon akin to RNA interference, we call it 'Protein interference' which can be exploited for knocking down protein variants of interest to a specificity single amino acid or allelic difference. This new method offers not only a valuable tool for biological research but also paves way for a novel therapeutic approach to target proteins in allele specific manner.
Results
Expression of protein variants in living cells were inhibited when high affinity monoclonal antibody raised against the linear peptide sequence of the antigen was delivered intracellularly. We show here that the levels of exogenously expressed green fluorescent protein (GFP) were significantly suppressed by the intracellular delivery of monoclonal antibodies raised against GFP ( Figure. 1) . Monoclonal antibodies (mAbs) raised against post-translational modifications such as phosphorylated tyrosine 4G10 did not deplete the levels of GFP. Interestingly, sequence specific downregulation of endogenous protein variants occurred when point-mutation specific mAbs were transfected to cells of different genotypes. Depletion of germline variants encoded by the single nucleotide polymorphism (SNP) rs351855, namely FGFR4 p.Gly388Arg (humans) and FGFR4 p.Gly385Arg (mouse) was observed when point-mutation specific mAbs were transfected to human and mouse cells of different genotypes respectively ( Figure. 2 and Figure. 3). The decreased levels of protein variant were verified by the abolishment of gain of function phenotype by the rs351855 SNP (Ulaganathan et al, 2015) in the germline genome. Interestingly, using this approach we succeeded in depleting challenging somatic variants namely BRAF p.V600E ( Figure. Two days after protein transfection immonoblot analysis was performed using conformation specific secondary antibody that does not detect intracellular delivered IgG (first image) or conventional secondary antibodies. GFP expression was substantially depleted when immunoglobulins binding to GFP epitope was delivered whereas HA tag specific mAbs that did not bind to GFP target unaltered its expression. On the other hand phosphotyrosine specific mAb specific against post-translational modification instead of primary amino acid sequence did not result in downregulation rather resulted in an increased expression of GFP. 
Figure 2. Precise depletion of Fgfr4 germline variant (FGFR4 p. G385R) in mouse cells

Fig. 6 KRAS p.G12V somatic variant-specific inhibition of growth in co-cultivated cells
Mouse embryonic fibroblasts (MEFs) stably expressing somatic variants namely human BRAF p.V600E and human KRAS p.G12V were genetically labelled using GFP and RFP expressing constructs respectively. All exogenous expression was directed by CAG promoter and are stably 
Figure 8. Generation of genetic reporters for screening and optimization protocols
Transposon based reporter expression plasmids shown above were constructed for generating stable cell lines. These cell lines were used for functional assays as well as for downstream protocols such as for screening assays, confocal live FRET imaging, mass spectrometry and co-culture assays.
Importantly, multiple epitope proteins were expressed using self-cleavable peptide sequences to allow stoichiometric expression and to answer if inhibiting translation of one epitope interferes with others.
This will be suggestive of mRNA knockdown.
Figure 9. Inhibition of polycistronic target expression
Sorted HEK293T cells stably expressing HA-FGFR4 Arg388-GFP epitope reporter#2 (shown above)
were transfected in replicates with indicated mAbs. Two days after treatment, cells were imaged at 10 X magnification for monitoring the target specific effects as indicated by GFP expression. Shown are representative images from one of three independent experiments. Green: GFP fluorescence and Blue:
Nuclear staining by Hoechst 33342.
Methods
Cell lines and Medium
Mouse embryonic fibroblasts (MEFs) were generated from wild type and rs351855 SNP-knock in mice as described before (Ulaganathan et al, 2015) 1 . Human cancer cell lines used in this study were as follows NCI-H1944 (Lung), NCI-H1838 (Lung), BXPC3 (Pancreas), PANC1 (Pancreas), HACAT (Skin) and SK-MEL-3 (Skin). All cell lines used were obtained from American Type Culture Collection (ATCC) and authenticated in-house using a StemElite ID system (Promega, G9530). None of the cell lines used in this study were in the International Cell Line Authentication Committee list of currently known cross-contaminated or misidentified cell lines. Cell lines maintained by our cell bank staff are routinely controlled for mycoplasma contamination. The cell lines used in this study were confirmed to be free of any mycoplasma contamination.
Plasmid Expression Constructs
Multi-cistronic transposon based plasmid constructs were generated by LRII clonase reaction between pENTRY-D TOPO entry vector and destination vector containing ITR-CAG-dest-IRES-puro-P2A- 
Generation of stable cell lines
Stable cell lines were generated by co-transfection in 1:1 ratio of pCMV-SB transposase and ITRplasmids and selected by puromycin resistance for a week followed by three rounds of flow cytometry sorting using BD FACSAriaIII.
Immunoprecipitation
Stable engineered cell lines were lysed using RIPA buffer (#9806, Cell Signaling) and HA-tagged proteins and Venus fluorescent proteins were immunoprecipitated using HA-tag (C29F4) Rabbit mAb (Magnetic Bead Conjugate) (#11846, Cell Signaling) and GFP-Trap_M (#gtm-20, Chromotek) beads respectively. BCA-normalized lysates were incubated with magnetic beads at 4 degrees Celsius for 4
hours. Interacting proteins were isolated from the lyaste using magnets and washed with RIPA buffer three times.
Western Blot analysis
Whole-cell lysates were prepared using 1× cell lysis buffer (Cell Signaling, 9803) 
Intracellular-delivery of mAbs
Preservative-free formulations of mAbs in PBS were conjugated to cationic lipids using ProJECT (#89850, ThermoScientific) reagent as per manufacturer's instruction manual and delivered to cells in serum-free cultivation medium. Two days post delivery, cells were washed and lysed in 1X cell lysis buffer (#9803, Cell Signaling). Mutation specific mAbs namely B-raf (V600E), Cat# 26039 and Ras (G12D), Cat# 26036 were obtained from NewEast Biosciences. FGFR4 pG388R variant specific mAbs reactive against mouse and human epitopes were custom made using services from AbPro Labs.
Flow cytometry
GFP and RFP labelled cells and co-cultivated cells were analysed using FACS Calibur (BD Biosciences) in cold PBS.
Fluorescence microscopy
Confocal imaging of GFP and RFP labelled cells was done using Lecia TCS SP8 microscope (Leica Microsystems).
Knock-down of GFP expression two days after intracellular delivery of lipid-conjugated antibodies, cells were imaged using Cellomics ArrayScan VTI HCS Reader (Thermo Scientific) using Hoescht filters and GFP filters.
